EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies

Rémy Duléry, Eolia Brissot, Mohamad Mohty

Blood Reviews · 2023-11 · 62 · 101080

DOI: 10.1016/j.blre.2023.101080 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood Reviews, 2023-11. Verfasst von Rémy Duléry und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, …. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematologic Neoplasms, Bronchiolitis Obliterans Syndrome, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 150 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In search of an ideal partner or alternative to conventional immunosuppressive agents, rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide (PT-Cy) have both emerged as valid and efficient options for preventing graft-versus-host disease (GvHD). To further reduce the risk of GvHD, strategies combining ATG and PT-Cy have recently been investigated. In a haploidentical setting, retrospective studies suggest that combining PT-Cy and ATG may result in a lower incidence of chronic GvHD without increasing the risks of infection or relapse, when compared to PT-Cy without ATG. In haploidentical or unrelated donor settings, adding reduced doses of PT-Cy to ATG may reduce the risk of acute and chronic GvHD and improve survival, particularly GvHD-free, relapse-free survival (GRFS), when compared to ATG without PT-Cy. Overall, the combination of PT-Cy and ATG is a safe and promising approach for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematologic NeoplasmsBronchiolitis Obliterans SyndromeHematopoietic Stem Cell TransplantationHumansAntilymphocyte SerumRetrospective StudiesNeoplasm Recurrence, LocalCyclophosphamideTransplantation Conditioning

Stichwörter der Autor:innen

Antithymocyte globulinGraft-versus-host diseaseHaploidentical hematopoietic cell transplantationHematological malignanciesPost-transplant cyclophosphamide

Substanzen

Antilymphocyte SerumCyclophosphamide

Autor:innen und Institutionen

  • Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Pa…

Zitieren

APA

Duléry, R., Brissot, E., & Mohty, M. (2023). Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Reviews, 62, 101080. https://doi.org/10.1016/j.blre.2023.101080

Vancouver

Duléry R, Brissot E, Mohty M. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Reviews. 2023;62:101080. doi:10.1016/j.blre.2023.101080

BibTeX
@article{Dulry2023,
  author = {Duléry, Rémy and Brissot, Eolia and Mohty, Mohamad},
  title = {Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies},
  journal = {Blood Reviews},
  year = {2023},
  volume = {62},
  pages = {101080},
  doi = {10.1016/j.blre.2023.101080}
}
Kostenlos starten →